{'fraction_non_alphanumeric': 0.03669724770642202, 'fraction_numerical': 0.0034403669724770644, 'mean_word_length': 6.214876033057851, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A New Method for Percutaneous Drug Delivery by Thermo‐Mechanical Fractional Injury

Percutaneous drug delivery (PDD) is a means of increasing the uptake of topically applied agents into the skin. Successful delivery of a photosensitizer into the skin is an important factor for effective photodynamic therapy. To evaluate the efficacy of pretreatment by thermomechanical fractional injury (TMFI) (Tixel®, Novoxel®, Israel) at low‐energy settings in increasing the permeability of the skin to a known hydrophilic‐photosensitizer medication, 5‐amino‐levulinic‐acid hydrochloride (ALA) in compounded 20% ALA gel. To compare the effect of TMFI on ALA permeation into the skin in compounded gel to three commercial photosensitizing medications in different vehicles: ALA microemulsion gel, methyl‐amino‐levulinic‐acid hydrochloride (MAL) cream, and ALA hydroalcoholic solution.